Researchers discovered that bacterial immune systems detect viral infections when viral enzymes cleave crucial host sensor molecules. This newly identified activation mechanism for the CBASS defense pathway opens pathways for developing advanced phage therapies to treat resistant bacterial infections.
University of Utah Health Research Reveals Viral Protease Triggers
Scientists investigating novel antimicrobial treatments are increasingly looking to bacteriophages, viruses that specifically target and destroy harmful bacteria without damaging human cells. While these phages offer a promising route around antibiotic resistance, therapeutic development hits a major roadblock because bacteria possess sophisticated native immune defenses.
A recent study published in Science outlines how microbes spot an incoming viral assault. Rather than scanning exclusively for foreign genetic material, bacterial cells register an attack when a viral enzyme directly damages a vital intracellular sensor molecule. Because bacterial reproduction happens so quickly, researchers leverage them to rapidly address questions regarding immune function before validating those findings in more human-relevant models.
CBASS Last Resort Defense Mechanism and Viral Proteins
The investigation centers on a prokaryotic immune network known as CBASS. When triggered, CBASS initiates a drastic self-sacrifice protocol, forcing the infected bacterium to destroy itself before the invading virus can replicate and spread to neighboring microbes. Because this extreme response proves fatal to the host cell, the system requires absolute precision in detecting genuine viral threats.
Researchers determined that this sensing mechanism detects a molecule that the virus needs to survive. Certain phages utilize specialized enzymes to degrade proteins during infection, and the bacterial defense system capitalizes on that exact activity.
Certain kinds of phages have a protein called a protease, which degrades other proteins, We found that the protease from the phage actually acts directly on the host protein, and that is the signal that turns on the whole signaling pathway.
Sam Hobbs, assistant professor of biochemistry at University of Utah Health
This mechanism differs sharply from related antiviral immune systems that recognize viral genetic material directly. Within CBASS, activation is instead triggered by a viral protein operating on a bacterial host protein, establishing an entirely novel pathway for how such host proteins become activated.
This is a totally new mechanism for how these host proteins are activated, I never would have guessed that this was the way it was going to work.
Sam Hobbs, assistant professor of biochemistry at University of Utah Health
Evolutionary Connections to Human Immunity and Future Therapeutic Goals
Beyond explaining microbial survival tactics, decoding the CBASS pathway provides broader insight into immunology. The bacterial defense system shares structural and functional ties with immune pathways found in humans, indicating that these systems are conserved between bacteria and humans and have been maintained in these different organisms for their entire evolutionary trajectory.
Reaching this breakthrough served as an absolute eureka moment for the team, laying the groundwork to engineer superior phage treatments capable of bypassing bacterial defenses. The study was published Oct. 1 in Science as “Phage proteases activate CBASS antiphage immunity,” with Sam Hobbs serving as first author alongside co-author Philip J. Kranzusch, a professor of microbiology at Harvard Medical School, as noted in reporting from Mirage News.
The fact that these systems are conserved between bacteria and humans suggests that they’ve been maintained in these different organisms for that entire evolutionary trajectory, The cells are telling us that this is a really important pathway because they’ve maintained it for billions of years. It’s incredibly fascinating, and it’s a cool window into what’s important in maintaining the ability to fight viruses.
Sam Hobbs, assistant professor of biochemistry at University of Utah Health
Funding for the project came from the Pew Biomedical Scholars program, the Burroughs Wellcome Fund, and support was also provided by Mathers Foundation, the Cancer Research Institute (CRI3996), the Parker Institute for Cancer Immunotherapy, the Massachusetts Consortium on Pathogen Readiness, and the National Institute of General Medical Sciences of the National Institutes of Health (1DP2GM146250-01).